Menu Search
Equities

KDA Group Inc

KDAGF:PKC

KDA Group Inc

Actions
  • Price (USD)0.1882
  • Today's Change0.00 / 0.00%
  • Shares traded2.93k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 17:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KDA Group Inc. is a Canada-based company focused on the development and marketing of its technological products and specialized software solutions for the healthcare market. The Company operates through Pharmaceutical Technology segment. It is focused on developing its technological products across four different platforms: KRX Medical, KRX Dental, KRX Cannabinoid and Adherize (ADRX). The KRX Dental is an electronic prescription platform assisting dentists in their practice. The KRX Medical is an electronic prescription platform assisting physicians in their practice. The KRX Cannabinoid is an electronic prescription platform assisting physicians in their practice when prescribing medical cannabis. The ADRX platform offers content allowing healthcare professionals (doctors and pharmacists) to virtually present various information. The platform includes various modules: Intelligent dialogue system, online questionnaire, pharmacist dashboard, developed algorithms, and a patient portal.

  • Revenue in CAD (TTM)204.14k
  • Net income in CAD-876.18k
  • Incorporated2008
  • Employees--
  • Location
    KDA Group IncBureau 300, 1351, rue Notre-Dame EstTHETFORD MINES G6G 0G5CanadaCAN
  • Phone+1 (514) 715-0376
  • Fax+1 (418) 755-0822
  • Websitehttp://www.alliancepharma.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.